Abnova Taiwan Corp. · TWSE:4133

Abnova Taiwan — Investor Presentation (November 2022)

22 slides from Abnova Taiwan's investor presentation, Nov 23, 2022

  1. Slide 1: 2022年法人說明會

    亞諾法生技股份有限公司 (4133.TW) 2022年法人說明會 2022/11/23 Innovate through Integrated Solutions www.abnova.com.tw

  2. Slide 2: 免責聲明

    免責聲明 本簡報及同時發佈之相關訊息包含財務、市場暨產品業務等預測性資訊。本 公司未來實際發生的營運結果及財務狀況可能與這些預測性資訊所明示或暗 示的預估有所差異，其原因可能來自於各種本公司所不能掌控的風險。這些 預估及展望的訊息，反應本公司截至目前為止對於未來的看法，本公司並不 負責隨時提醒或更新。 2

  3. Slide 3: 今日議程

    今日議程 1 亞諾法公司簡介 亞諾法公司介紹與沿革 2 亞諾法財務成果 合併損益表與產品別營收分析 3 亞諾法產品系列簡介 2022年最新產品開發進展 3

  4. Slide 4: 亞諾法公司簡介

    1 亞諾法公司簡介 4

  5. Slide 5: Company Overview

    Ol|| sexo5neans ‘Company name: Abnova Corporation Founded Date = January 4th, 2002 Public Listing Date: December 28th, 2009 (TWSE: 4133) aA Headquarter 9th Floor, 108 Zhouzi St., Neihu Dist., Taipei City, Taiwan (ROC) re Factory Address: No, 326-8, Sec. 4, Znongzheng Rd., Zhongli Dist., Taoyuan City

  6. Slide 6: 6

    6

  7. Slide 7: Featured products and e-newspaper

    [| SARE | RNeTy aren | WEMGAgE examen CHEK vmoe BMRAREE everson + senteccatpau lt Pemesealeras Shlegecsems November E-newspaper: AESERE fae ‘phony Patsy :°E@ =: a Lr daa RRR Nov. Featured Products weaanenanssn ‘ eerie SHH sre FISH Probes ign sceofeanscneyto ze Dawe ee i Infectious Disease ELISA Kits

  8. Slide 8: Product categories

    aawRasS Se5A | MEEK 2808 SERE AAR BREN AEMRASE SARSCovICOV2 => BMASRNA ° SARS-CoV/CoV-2 Froieins/Peptides > Marae Ab > DNAKFaD™ > Folycionat AD > wecoane L Recombinant Ap * Conjugate Ab . — ~ In Situ Hybridization Lysates/Staes > ieclicaiiie = Circulating Rare Cell Ab ATssIEArays > LRSEAESNOE AE zs

  9. Slide 9: 亞諾法財務成果

    2 Ta SESA ALIS ER

  10. Slide 10: 合併損益表

    合併損益表 Q3‘22 % Q3‘21 % Q1~Q3‘22 % Q1~Q3‘21 % Q1~Q3 YOY 營業收入 101,602 100.00% 116,024 100.00% 303,778 100.00% 354,606 100.00% -14.33% 營業成本 52,429 51.60% 62,363 53.75% 156,719 51.59% 195,740 55.20% 19.94% 營業毛利 49,173 48.40% 53,661 46.25% 147,059 48.41% 158,866 44.80% -7.43% 營業費用 -34,378 -33.84% -37,367

  11. Slide 11: 產品別營收分析

    > ))) Beet In NT$K 500,000 2022 Jan~Oct 450,000 400,000 Others body 63% Proteii 100,000 217,937 VAONYV 2021 2022 Jan~Oct @Antibody © Protein ™ Others

  12. Slide 12: 亞諾法產品系列簡介

    3 亞諾法產品系列簡介 12

  13. Slide 13: Abnova Product Family

    亞諾法產品系列簡介 SAM, mRNA, circRNA OM-PBAE, cKK-E12, C12-200 LNP circRNA COVID-19 疫苗 Abnova Product Family mRNA Omicron 疫苗 Cytokine RNA LNP 肝癌治療 PsAg RNA LNP 攝護腺癌疫苗 13

  14. Slide 14: SAM, mRNA, circRNA

    SAM, mRNA, circRNA SAM Construct 5: 3 Encapsulate ee th” *GOI: Gene of interest mRNA Construct ey 3 (Ae) IGG UTR—sannnaa *GOI: Gene of interest sgt, Encapsulate i % circRNA Construct > IRES Encapsulate —> Gene of interest

  15. Slide 15: OM-PBAE, cKK-E12, C12-200 LNP

    OM-PBAE, cKK-E12, C12-200 LNP 15

  16. Slide 16: circRNA COVID-19 疫苗

    circRNA COVID-19 2 circRNA Construct Encapsulate *GOI: Gene of interest circRNA Preparation Target Gene Plasmid circRNA Preparation Cloning Preparation T7 promoter Target Gene = fe) Ta PS aa SOS DNA sequence ud 4 \— GO) wre — |ranecrptin —> Orme OT + Sem —~ C) 50) Sas RNa mmm RNA transcript E.coli P

  17. Slide 17: circRNA COVID-19 疫苗

    circRNA COVID-19 疫苗 Data : S1+S2 circRNA Vaccine induce High Titer Antibody Response Against SARS-CoV2 Pseudovirus 17

  18. Slide 18: mRNA Omicron 疫苗

    mRNA Omicron 疫苗 Background SARS-CoV-2 Omicron variant was first identified in mid-November 2021 and rapidly became the dominant variant in many countries. Spread of the Omicron variant, which led to increased hospitalizations for COVID-19, generated concern about immune evasion and the duration of p

  19. Slide 19: mRNA Omicron 疫苗

    | mRNA Omicron 4 Data @ RBD vs S1+S2 MRNA Vaccines Induce High Titer Antibody Response Agi Target Proteins ‘Mouse sera was evaluated 35 days and 42 days after administration with 5 ug pK1-Omicron RBD and 5ug pK-Omicron $1+82 vaccines using ELISA \st SARS-CoV-2 Omicron Variant 5 5 4 ‘ a Se gee g 3 og

  20. Slide 20: Cytokine RNA LNP 肝癌治療

    | Cytokine RNA LNP Bt #834 y can Cytokine RNA ° Construct 3 UR aw Encapsulate Liver cancer cell implantation Liver cancer growth in mouse No treatment Treatment Tumor weight (9) 6 00 18: 05. No treatment Treatment (n=3) (n=3) jo treatment Treatment

  21. Slide 21: PsAg RNA LNP 攝護腺癌疫苗

    | PsAg RNA LNP $a A 88 BA PsAg (prostateAg) © Ey Encapsulate x a RNA Construct Le -———w if ww) rae Cytotoxicity assay of PsAg specific stimulation prostate cancer cells e Prostate Poh specific cancer cells» 100 CD8+ T cell ) # CD8+ T cells 2 @ PSAGHHLA.A2+ Spleen Ae Psvgemtaaze go Pangontacas- - @ @

  22. Slide 22: Thank You

    Thank You Abnova Innovate through Integrated Solutions

Abnova Taiwan — Investor Presentation (November 2022) on 6ix